Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de fase 3, doble ciego, controlado con placebo (Parte A) con una extensión abierta (Parte B) que evalúa MM120 en comparación con placebo en el trastorno de ansiedad generalizada

24 de septiembre de 2026 actualizado por: Definium Therapeutics US, Inc.

Un estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 12 semanas (Parte A) con una extensión abierta de 40 semanas (Parte B) que evalúa la eficacia y seguridad del MM120 oral en comparación con el placebo en el Tratamiento de adultos con trastorno de ansiedad generalizada - Voyage

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.

The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.

Tipo de estudio

Intervencionista

Inscripción (Actual)

214

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Gilbert, Arizona, Estados Unidos, 85234
        • Lighthouse Psychiatry
      • Scottsdale, Arizona, Estados Unidos, 85022
        • Scottsdale Research Institute
    • California
      • La Jolla, California, Estados Unidos, 92037
        • Kadima Neuropsychiatry Institute
      • San Francisco, California, Estados Unidos, 94158
        • UCSF Department of Neurology
      • Santa Monica, California, Estados Unidos, 90404
        • Psychedelic Science Institute
    • Colorado
      • Denver, Colorado, Estados Unidos, 80209
        • Mountain View
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Clinical Neuroscience Solutions Inc.
      • Lauderhill, Florida, Estados Unidos, 33319
        • Segal Trials
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30331
        • Atlanta Center for Medical Research
      • Decatur, Georgia, Estados Unidos, 30030
        • iResearch Atlanta
      • Savannah, Georgia, Estados Unidos, 31405
        • CenExel iResearch, LLC
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60640
        • Uptown Research Institute
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02116
        • Adams Clinical Boston
      • Watertown, Massachusetts, Estados Unidos, 02472
        • Adams Clinical Watertown
    • New Jersey
      • Marlton, New Jersey, Estados Unidos, 08053
        • Hassman Research Institute
    • New York
      • New York, New York, Estados Unidos, 10021
        • Spectrum Neuroscience and Treatment Institute
      • New York, New York, Estados Unidos, 10032
        • New York State Psychiatric Institute (NYSPI)
      • New York, New York, Estados Unidos, 10029
        • Adams Clinical Harlem
      • The Bronx, New York, Estados Unidos, 10461
        • Adams Clinical Bronx
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44113
        • Cleveland Clinic Lutheran Hospital
    • Oregon
      • Portland, Oregon, Estados Unidos, 97210
        • Summit Headlands LLC
    • Pennsylvania
      • Moosic, Pennsylvania, Estados Unidos, 18507
        • Scranton Medical Institute
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Adams Clinical Philadelphia
    • South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38119
        • Clinical Neuroscience Solutions, Inc.
    • Texas
      • Austin, Texas, Estados Unidos, 78712
        • University of Texas at Austin
      • Austin, Texas, Estados Unidos, 78759
        • BioBehavioral Research of Austin
      • Austin, Texas, Estados Unidos, 78737
        • Austin Clinical Trial Partners
      • Dallas, Texas, Estados Unidos, 75231
        • FutureSearch Trials of Dallas, LLC
      • DeSoto, Texas, Estados Unidos, 75115
        • Adams Clinical Dallas
    • Utah
      • Draper, Utah, Estados Unidos, 84020
        • Cedar Clinical Research
      • Orem, Utah, Estados Unidos, 84058
        • Inner Space Research
    • Vermont
      • Bennington, Vermont, Estados Unidos, 05201
        • Memory Clinic Inc.
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • Seattle Neuropsychiatric Treatment Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 74 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Diagnosis of GAD per DSM-5
  2. Male or female aged 18 to 74
  3. HAM-A Total Score ≥20

Exclusion Criteria:

  1. Certain psychiatric disorders (other than generalized anxiety disorder)
  2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
  3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
  4. Any clinically significant unstable illness

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Arm 1 - Placebo

A substance that is designed to have no therapeutic value

A substance that is designed to have no therapeutic value

Experimental: Arm 2 - 100µg DT120

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Otros nombres:
  • tartrato de lisérgida
  • MM120
  • LSD D-Tartrate

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Periodo de tiempo: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
Periodo de tiempo: Day 2 to Week 12

The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening.

Day 2 to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Periodo de tiempo: Baseline to Week 12

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Periodo de tiempo: Baseline to Week 12

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
Periodo de tiempo: Baseline to Week 12

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 12
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
Periodo de tiempo: Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
Periodo de tiempo: Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
Periodo de tiempo: Baseline to Week 52

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Periodo de tiempo: Baseline to Week 52

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Periodo de tiempo: Baseline to Week 52

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
Periodo de tiempo: Baseline to Week 52

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
Periodo de tiempo: Baseline to Week 52

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 52
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
Periodo de tiempo: 40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
Periodo de tiempo: Week 8, Week 4, Week 2, and Week 1

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Week 8, Week 4, Week 2, and Week 1
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Periodo de tiempo: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
Periodo de tiempo: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Periodo de tiempo: Baseline to Week 12

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
Periodo de tiempo: Baseline to Week 12

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 12
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
Periodo de tiempo: Day 1 to Week 52

Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period

Day 1 to Week 52
Time to first treatment or lack of efficacy in the open-label period (Part B)
Periodo de tiempo: Day 1 to Week 52

Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy

Day 1 to Week 52
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
Periodo de tiempo: Day 1 to Week 52

Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension.

Day 1 to Week 52
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
Periodo de tiempo: 40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
Periodo de tiempo: 40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
CSFQ-14 total score at each timepoint assessed during the open-label period
Periodo de tiempo: 40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de diciembre de 2024

Finalización primaria (Actual)

15 de julio de 2026

Finalización del estudio (Estimado)

1 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de diciembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

16 de diciembre de 2024

Publicado por primera vez (Actual)

18 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • MM120-300

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .